Masitinib 'shows promise' in treating MS

[MSUK]

Progressive multiple sclerosis patients treated with AB Science’s lead compound AB07002 (masitinib) in a Phase III clinical trial showed positive results in a non futility test (a test to determine if an experimental therapy shows some sign of efficacy)..... Read More - http://www.ms-uk.org/emergingtherapies